All In MedTech

Device Trial Radar · NCT06888687

Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.

Continuous Glucose Monitoring-Assisted Remote E-health Dietetics to Empower People With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

May 12, 2025

Primary completion

Nov 28, 2026

Study completion Nov 28, 2026

Sponsor

Lead sponsor
Australian Catholic UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott Diabetes Care; University of Adelaide; The University of Queensland; Monash University; University of Melbourne; Deakin University
First posted
Mar 21, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Continuous Glucose Measurement
  • Dietary Modification

Interventions

  • Dietetic supportBehavioral

    Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.

  • Continuous glucose monitoringDevice

    Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: baseline, 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Australian Catholic University

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.